$6.470
0.000 (0.00%)收盘时
SVA 资讯
SVA 事件
Sinovac Biotech Regains Nasdaq Compliance Status
Sinovac Biotech announced that it received a notification letter dated May 20, 2026 from Nasdaq Listing Qualifications stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) and 5250(c)(2), as required by the Panel's decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel's decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel's decision. The Notification Letter also stated that the Company will be subject to a mandatory panel monitor for a period of one year from the date of such letter. If, within that one-year monitoring period, the Nasdaq Listing Qualifications staff finds the Company again out of compliance with the Periodic Filing Rule that was the subject of the exception, the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Panel if the initial Panel is unavailable. The Company will have the opportunity to respond and present to the Panel as provided by Nasdaq Listing Rule 5815(d)(4)(C).
Sinovac Biotech Granted Nasdaq Continued Listing Approval
Sinovac Biotech announced that the Nasdaq Hearings Panel has granted the company's request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and remediation of filing delinquencies. Under the Panel's decision, Sinovac must, on or before May 11, 2026, demonstrate compliance with Nasdaq Listing Rule 5250(c)(1) and Listing Rule 5250(c)(2) by completing filings of its annual report for the year ended December 31, 2024 on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of year 2025 on Form 6-K.
Sinovac Biotech Receives Nasdaq Compliance Notification, Faces Delisting Risk
Sinovac Biotech announced that it has received a notification letter dated January 2, 2026 from Nasdaq Listing Qualifications, stating that the Company was not in compliance with Nasdaq's Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025. As previously disclosed, the Company received a delisting determination letter from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq Hearings Panel to appeal the Staff Determination on November 19, 2025. Nasdaq has informed the Company that the Nasdaq Hearings Panel will also consider the matter addressed in the Notification Letter at a hearing scheduled for January 8, 2026 at which the Company has been invited to present its views regarding this matter.
Sinovac Biotech Board Members Confirmed Until 2026
Sinovac Biotech announced that the Antigua High Court has ordered that the directors Simon Anderson, Shan Fu, Shuge Jiao, Yuk Lam Lo, Yumin Qiu, Yu Wang, Andrew Yan and Yin Weidong, will comprise the board of the company until the trial listed in late April/early May 2026. The Antigua High Court decision arises from a hearing that took place on October 27, at which applicants SAIF Partners, OrbiMed Partners Master Fund and 1Globe Capital each sought injunctions to confirm the composition of their respective favored boards, pending determination of a dispute over the outcome of the company's special shareholders meeting on July 8. The hearing of the SSM Dispute has been scheduled to take place in the Antigua High Court in late April/early May 2026, with judgment to be delivered by the Court thereafter. A board meeting was held on December 17 to make efforts to restore trading of the company's shares on Nasdaq, to explore opportunities to properly and legally resolve the company's ongoing disputes, and to take all necessary steps, including to facilitate to reach agreements among all parties. Andrew Yan, chairman of the board of Sinovac, stated, "The current Board is committed to the long-term and sustainable development of the Company. The Board and its Audit Committee will collaborate closely with the auditors to complete audit. The Board trusts and supports the CEO and management team in continuing to implement the Company's current development strategy, maintaining operational stability, continuously enhancing shareholder value through sustained business growth, and collaboratively promoting the comprehensive development of the Company."
Sinovac Biotech Investors Show Backing for Dividend Payout
Sinovac Biotech shareholder Heng Ren Silk Road Investments LLC "announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared by the board. Sinovac's stock has been halted from trading since 2019. As a result, Sinovac shareholders missed out on an extraordinary windfall from the success of its COVID-19 vaccine, CoronaVac, and its billions of dollars in sales during the pandemic due to the trading halt. In July 2025, the current Board paid a $55.00 dividend to shareholders as partial compensation for dividends that had not been paid during the trading halt. The board declared an additional $19.00 dividend per common share on June 17, 2025. The dividend was announced as part of the current board's effort to pay independent Sinovac shareholders dividends they did not receive but which had been paid to certain affiliates and insiders who were minority shareholders of Sinovac subsidiaries. More than four months later, Sinovac has failed to announce record and payment dates for the declared dividend. Sinovac's failure to provide an update on the promised dividend is especially surprising as both the current board and the SAIF-led consortium that is seeking to replace the current board campaigned on the promise to pay dividends to benefit Sinovac shareholders."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。